Raul R. Rodriguez - President and Chief Executive Officer
Raul R. Rodriguez is the President and Chief Executive Officer of Rigel and serves on our Board of Directors. Before being named CEO in November 2014, Mr. Rodriguez held management positions of increasing responsibility within the company, most recently serving as President and Chief Operating Officer since June 2010. He joined Rigel as Vice President, Business Development in April 2000. Prior to his employment at Rigel, Mr. Rodriguez was Senior Vice President, Business Development and Operations for Ontogeny, Inc. (now Curis); Executive Director, Business Development and Market Planning for Scios, Inc. (now J&J); and held various positions at G.D. Searle & Company (now Pfizer). After earning his A.B. from Harvard College, Mr. Rodriguez went on to earn his Masters of Public Health at the University of Illinois and his M.B.A. at the Stanford Graduate School of Business.
Eldon C. Mayer III - Executive Vice President and Chief Commercial Officer
Eldon C. Mayer III was appointed as Executive Vice President and Chief Commercial Officer in October 2016. Prior to joining Rigel, Mr. Mayer successfully led the commercial strategy function at Questcor Pharmaceuticals, a Specialty BioPharma company that focused on serious, ultra-rare diseases. As head of commercial operations, Mr. Mayer launched a drug in many new indications, building out a specialty commercial team from 10 to nearly 500 people and growing annual sales to over $1 billion. Prior to that, he held positions of increasing responsibility at a number of biopharma companies including Schering-Plough, ALZA, Chiron, and Connetics, in functional areas including strategic planning, marketing, sales, market research/analytics, operations and finance. Mr. Mayer serves as a member of the Board of Directors for Eiger Biopharmaceuticals, Promet Therapeutics LLC and the National Community Oncology Dispensing Association. Mr. Mayer holds a BS in Finance from Fairleigh Dickinson University and an MBA in Marketing from Syracuse University.
Anne-Marie Duliege, M.D. - Executive Vice President and Chief Medical Officer
Anne-Marie Duliege, M.D., M.S. has served as our Executive Vice President and Chief Medical Officer since March 2016. Prior to joining Rigel, Dr. Duliege was Chief of Strategic Development and Head of Immuno-oncology at ChemoCentryx, Inc. From 2004 to 2013, Dr. Duliege was at Affymax Inc., initially as Vice President, Clinical, Medical and Regulatory Affairs, and then as Chief Medical Officer. At Affymax, she grew the Clinical Development organization and successfully managed the development of its first marketed product through international clinical studies, resulting in NDA approval by the FDA. In that role, she was responsible for working closely with the FDA on product label and post-marketing requirements, as well as the strategy and implementation of significant post-launch epidemiological studies. She was also responsible for providing critical pipeline development results in support of the Affymax initial public offering and follow-on public offerings, led a major partnership with Takeda, Inc. and contributed to business development projects. Before Affymax, Dr. Duliege worked at Chiron and Genentech. Dr. Duliege received her Doctorate of Medicine, her certification in Pediatrics, and an M.S. in Biostatistics from Paris Medical School, and an M.S. in Epidemiology from the Harvard School of Public Health. She is an Adjunct Clinical Assistant Professor at Stanford’s School of Medicine and the Lucile Packard Children’s Hospital. She also serves on the board of the CIRM, the California Institute for Regenerative Medicine.
Dolly Vance - Executive Vice President, Corporate Affairs and General Counsel
Dolly Vance has been our Executive Vice President, Corporate Affairs and General Counsel since May 2010. Ms. Vance is also Rigel's Corporate Secretary, a title she has held since 2006. She was appointed Senior Vice President and General Counsel in 2007 and was appointed General Counsel and Vice President of Intellectual Property in January 2003. She joined Rigel in September 2000 as Rigel's first in-house counsel. From 1997 until September 2000, she was at the law firm of Flehr Hohbach Test Albritton & Herbert (now Dorsey & Whitney), where she was a partner. Prior to law school, she worked in various research laboratories, including the laboratory of Norman Davidson, at California Institute of Technology. She holds a bachelor's degree from University of California, San Diego and a J.D. degree from Boston University School of Law.
Stacy Markel - Executive Vice President, Human Resources
Stacy Markel was appointed Executive Vice President, Human Resources in March 2018. Prior to joining Rigel, Ms. Markel was the Senior Vice President of Human Resources at Portola Pharmaceuticals, Inc., where she helped successfully transition the company from a development stage company to a commercial stage company preparing the organization for the launch of their first marketed product. Prior to Portola, Ms. Markel served as the Senior Vice President of Human Resources and Professional Development at Actelion Pharmaceuticals, Ltd., where she was a member of the Executive Leadership Team and Global Human Resources Leadership Team from 2005 to 2015. She was instrumental in the successful growth of the organization and in positioning culture as a key advantage in attracting and retaining talent. Ms. Markel has over 25 years of business experience in the pharmaceutical/biotechnology industry. She began her career in sales and sales management with Roche Laboratories. Ms. Markel holds a bachelor’s degree from University of California, Davis.
Esteban Masuda, Ph.D. - Senior Vice President, Research
Esteban Masuda, Ph.D. was appointed Senior Vice President, Research in September 2016. Before being named to that position, Dr. Masuda held the title of Senior Vice President, Immunology since 2013. He joined Rigel as a scientist in 1998. He has worked on and led numerous drug discovery projects in inflammatory and allergic diseases, and served as the first project leader of the program that led to the discovery of fostamatinib. His work has resulted in: moving several product candidates into clinical development; establishing various corporate partnerships; producing 57 publications; and issuing 49 U.S. patents. Prior to joining Rigel, Dr. Masuda spent seven years at DNAX Research Institute of Molecular and Cellular Biology in cytokine biology. He received a B.S. in biochemistry from University of California, Riverside and a Ph.D. in molecular genetics from Hiroshima University, Japan.
Joseph Lasaga - Vice President, Business Development and Alliance Management
Joseph Lasaga was appointed Vice President, Business Development and Alliance Management in October 2016. Prior to rejoining Rigel, Mr. Lasaga was Vice President, Business Development and Alliance Management at Galena Biopharma, Inc., where he was responsible for managing corporate and business development strategy and activities. From 2010 until 2014, Mr. Lasaga was Director, and later named Senior Director, Business Development at Nektar Therapeutics, where he led licensing activities, managed key alliances and structured research collaborations. He began his career at Rigel in 1998, working in research before moving into business development, most recently as Associate Director. In that role, he served as the alliance manager for all of Rigel’s partners, was an integral member of the negotiating team for Rigel’s out-licensing of fostamatinib to AstraZeneca in early 2010, and managed all other aspects of business development. Mr. Lasaga graduated from San Jose State University with a B.S. in Molecular Biology and earned his M.B.A. in Marketing from San Francisco State University.